HT1376-luc Orthotopic Mouse Model Service for Bladder Cancer

The HT1376-luc orthotopic mouse model represents one of the most physiologically relevant platforms for studying muscle-invasive bladder cancer progression and evaluating novel therapeutic candidates in a native urothelial microenvironment. At Alfa Cytology, we specialize in constructing and validating this advanced preclinical model with integrated bioluminescence tracking, providing researchers with robust, reproducible data to advance their oncology pipelines from early discovery through late-stage candidate selection.

Overview of HT1376-luc Orthotopic Mouse Model for Bladder Cancer

The HT1376-luc orthotopic xenograft model is established by implanting luciferase-transduced HT1376 human bladder carcinoma cells directly into the murine urinary bladder, thereby recapitulating the anatomical location, stromal interactions, and pathophysiological progression characteristic of human muscle-invasive urothelial carcinoma. Unlike subcutaneous alternatives, this orthotopic approach preserves the native tumor–stromal crosstalk, vascular architecture, and immune contexture of the bladder wall, enabling tumor cells to engage with organ-specific extracellular matrix components and undergo molecular programs that more faithfully mirror clinical disease trajectories. The stable expression of firefly luciferase in HT1376-luc cells permits longitudinal, non-invasive quantification of tumor burden through bioluminescence imaging, offering a sensitive readout for monitoring exponential growth, spontaneous metastasis, and treatment-induced regression without repeated terminal sampling.

Fig 1. NIRF images and imaging analysis of Nectin4–IR700. The NIRF images in a SW780 (A) and HT1376-luc (B) tumor-bearing mouse. Quantitative analysis of fluorescence intensity (C) and target-to-background ratio (D) at the tumor site after infusing Nectin4–IR700 (n = 10). (Liu, Yongshun, et al., 2025)

Histologically, HT1376-derived orthotopic tumors exhibit high-grade urothelial morphology with prominent cellular and nuclear pleomorphism, elevated mitotic indices, and focal invasion into the muscularis propria—features that align closely with human high-grade muscle-invasive bladder cancer. The model has proven particularly valuable for interrogating cancer stem cell dynamics, chemotherapy resistance mechanisms, and intravesical drug delivery strategies, given the cell line's documented expression of stemness markers including CD44, CD47, and ALDH isoforms. Furthermore, the mixed basal-luminal molecular signature of HT1376 provides a unique substrate for subtype-specific drug profiling, bridging the gap between conventional 2D assays and clinically translatable preclinical outcomes.

Cell Line Information: HT1376-luc

HT1376-luc is a genetically engineered derivative of the HT1376 human bladder cancer cell line, stably transduced with a firefly luciferase reporter construct to enable real-time bioluminescent monitoring in vivo. The parental HT1376 line was originally isolated from a grade 3 transitional cell carcinoma of the urinary bladder in a 58-year-old Caucasian female patient and has been extensively characterized as a representative model of muscle-invasive urothelial carcinoma with basal-squamous molecular features. Key attributes of this cell line are summarized below:

Our Services

Alfa Cytology delivers end-to-end HT1376-luc orthotopic model services tailored to your discovery and development objectives—from pilot feasibility assessments and model construction to longitudinal imaging, histopathological endpoint analysis, and pharmacokinetic-pharmacodynamic integration. Our team works within fully accredited vivarium facilities under rigorous IACUC oversight, ensuring every study is executed with scientific precision, ethical integrity, and complete traceability.

Workflow of HT1376-luc Orthotopic Mouse Model Construction

Construction of the HT1376-luc orthotopic bladder cancer model follows a standardized, multi-step protocol optimized for high engraftment efficiency, reproducible tumor kinetics, and minimal procedural morbidity. The workflow integrates surgical catheterization, surface preconditioning, controlled cell instillation, and longitudinal bioluminescence monitoring, as outlined below:

1. Cell Preparation and Quality Control: HT1376-luc cells are expanded under low-passage conditions (passage 3–6) in antibiotic-free complete medium to preserve tumorigenic potential. Viability is confirmed by trypan blue exclusion (>95% viability required), and luciferase expression is validated via in vitro bioluminescence assay to ensure uniform reporter signal across the batch.
2. Animal Selection and Acclimation: Female athymic nude mice (6–8 weeks old) are selected based on anatomical suitability for transurethral catheterization. Animals are acclimated for one week under pathogen-free conditions, with daily health monitoring and body weight recording to establish baseline parameters.
3. Anesthesia and Bladder Evacuation: Mice are anesthetized with isoflurane (3% induction, 1.5–2% maintenance) and positioned supine on a heated surgical platform. The urinary bladder is gently evacuated by manual abdominal pressure to ensure an empty lumen for subsequent instillation.
4. Urethral Catheterization: A sterile 24-gauge pediatric venous catheter, lubricated with non-irritating gel, is inserted transurethrally into the bladder under aseptic technique. Proper placement is confirmed by visual inspection and gentle resistance at the bladder neck, avoiding deep insertion that could traumatize the bladder wall.
5. Bladder Surface Preconditioning: The bladder mucosa is pretreated with 50 µL of 0.1% poly-L-lysine (PLL) instilled slowly over 100 seconds to avoid vesicoureteral reflux. PLL adheres to the negatively charged glycosaminoglycan layer, enhancing electrostatic interaction with tumor cells. The solution is retained for 15–20 minutes before evacuation.
6. Tumor Cell Instillation: HT1376-luc cells (3 × 10⁶) in 50 µL PBS/Matrigel (1:1) are slowly instilled at 10 µL per 20 seconds. A single-cell suspension is critical to prevent clumping and ensure uniform tumor seeding across the bladder wall.
7. Dwell Period and Recovery: The urethral meatus is gently clamped to prevent leakage, and cells are retained in the bladder for 1.5 hours under continuous anesthesia with thermal support. Afterward, the clamp and catheter are removed, the bladder is allowed to empty spontaneously, and mice recover in a heated chamber until full mobility and normal micturition are restored.
8. Bioluminescence Imaging and Tumor Monitoring: Starting at day 7–10 post-implantation, tumor engraftment and growth are monitored via IVIS Spectrum or equivalent bioluminescence imaging system following intraperitoneal D-luciferin administration (150 mg/kg). Regions of interest are drawn around the bladder, and photon flux (photons/sec/cm²/sr) is quantified to track longitudinal tumor dynamics.
9. Endpoint Analysis and Histopathology: At study termination, mice are humanely euthanized and bladders are excised, weighed, and processed for formalin-fixed paraffin embedding. Serial sections are stained with H&E for morphology assessment, and immunohistochemistry is performed for Ki67, CD44, and human-specific markers to confirm tumor origin and proliferative index.

Fig 2. HT1376-luc Orthotopic Mouse Model construction workflow.

Case Study-HT1376-luc Orthotopic Mouse Model Development

In a representative preclinical engagement, HT1376-luc orthotopic tumors were established in immunodeficient mice to evaluate the efficacy of an investigational intravesical agent targeting urothelial cancer stem cell markers. Following successful engraftment verified by bioluminescence imaging within the first two weeks, animals were randomized into treatment and vehicle-control cohorts. Longitudinal BLI revealed distinct growth trajectories between groups, with treated animals showing attenuated photon flux accumulation compared to controls. Endpoint histopathology confirmed reduced tumor burden, decreased muscular invasion depth, and lower Ki67 proliferation indices in the treatment arm, while maintaining intact bladder architecture in responders. These findings supported the candidate's mechanism-of-action hypothesis and informed dose-selection for subsequent IND-enabling studies.

Why Choose Alfa Cytology?

Partnering with Alfa Cytology for your HT1376-luc orthotopic bladder cancer model program means gaining access to a scientifically driven, quality-first preclinical infrastructure designed to de-risk your therapeutic pipeline. Our distinguishing capabilities include:

• Deep expertise in urological oncology models, with optimized protocols that achieve consistent engraftment and physiologically relevant tumor progression in the native bladder microenvironment.
• Integrated bioluminescence imaging infrastructure allowing non-invasive, quantitative longitudinal tracking of individual tumor kinetics without confounding serial sacrifice artifacts.
• Rigorous cell banking and authentication procedures, including STR profiling, mycoplasma screening, and luciferase expression validation, to ensure model fidelity and reproducibility across studies.
• Flexible study designs accommodating single-agent efficacy, combination regimens, intravesical delivery optimization, and pharmacodynamic biomarker analysis tailored to your compound class.
• Comprehensive endpoint capabilities spanning digital histopathology, immunohistochemistry, multiplex immunofluorescence, and gene expression profiling to generate mechanistic insights alongside efficacy data.
• A dedicated project management structure that provides transparent reporting, milestone-driven timelines, and direct scientific consultation from study design through final report delivery.

Contact Us

Whether you are advancing a first-in-class intravesical therapy, a systemic regimen for muscle-invasive bladder cancer, or a targeted agent against urothelial cancer stem cells, Alfa Cytology stands ready to accelerate your preclinical program with our HT1376-luc orthotopic model expertise. Contact us today to discuss your study objectives, review our capabilities deck, and receive a customized proposal aligned with your timeline and budget. Our scientific team looks forward to collaborating with you to generate the high-quality, translationally relevant data your program demands.

For research use only. Not intended for any clinical use.